Guangzhou Baiyunshan Pharmaceutical Holdings Company (HK:0874) has released an update.
Guangzhou Baiyunshan Pharmaceutical Holdings Company has restructured a partnership agreement, introducing the State-owned Enterprise Innovation Fund as a new partner to the GP Venture Capital Fund. The agreement modification alters the investment ratio and reduces the GP Fund’s contribution from RMB 690 million to RMB 390 million without changing other core provisions. This connected transaction adheres to the Hong Kong Listing Rules and does not require independent shareholder approval.
For further insights into HK:0874 stock, check out TipRanks’ Stock Analysis page.
